![](/img/cover-not-exists.png)
Cost-effectiveness analysis of exenatide once-weekly versus dulaglutide, liraglutide, and lixisenatide for the treatment of type 2 diabetes mellitus: an analysis from the UK NHS perspective
Chuang, L. H., Verheggen, B. G., Charokopou, M., Gibson, D., Grandy, S., Kartman, B.Language:
english
Journal:
Journal of Medical Economics
DOI:
10.1080/13696998.2016.1203329
Date:
June, 2016
File:
PDF, 907 KB
english, 2016